Quel est le prix pour Radiopharm Theranostics Limited (RAD)

Le prix pour Radiopharm Theranostics Limited (RAD) est $0.00775813

Quelle est la capitalisation boursière pour Radiopharm Theranostics Limited (RAD)

La capitalisation boursière pour Radiopharm Theranostics Limited (RAD) est $18.35M

Radiopharm Theranostics Limited (RAD) Prix et Capitalisation Boursière

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Prix pour RAD	L’actif B	La capitalisation boursière de B	Résultats
$2,243.84 $18.35M	NVDA	$5.307T	+28,922,381.21%
$1,924.24 $18.35M	AAPL	$4.551T	+24,802,775.62%
$1,756.64 $18.35M	GOOG	$4.154T	+22,642,447.12%
$1,517.39 $18.35M	MSFT	$3.589T	+19,558,573.31%
$1,182.62 $18.35M	AMZN	$2.797T	+15,243,568.08%

Prix pour RAD

L’actif B

La capitalisation boursière de B

Résultats

$2,243.84 $18.35M